EGFR inhibition and more: A new generation growing up

Journal of Thoracic Disease

Volumn 4, Issue 6, 2012, Pages 553-555

  Enting, Deborah ^a   Spicer, James ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

CANCER SURVIVAL; COVALENT BOND; DRUG RESPONSE; DRUG TREATMENT FAILURE; EDITORIAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE DUPLICATION; GENE FREQUENCY; GENE INSERTION; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; POINT MUTATION; SIGNAL TRANSDUCTION;

EID: 84873658983     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.10.04     Document Type: Editorial

References (11)

1. Pao W, Miller V, Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11.
2. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-74.
3. Ramalingam SS, Blackhall F, Krzakowski M., et al. Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2012; 30: 3337-44.
4. Wu JY, Wu SG, Yang C.H., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008; 14: 4877-82.
5. Massarelli E, Varella-Garcia M, Tang X., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-6.
6. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
7. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transi Med 2011; 3:7Sra26.
8. Engelman JA, Janne PA Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-9.
9. Engelman JA, Zejnullahu K, Gale C.M., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67: 11924-32.
10. Li D, Ambrogio L, Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702-11.
11. Miller VA, Hirsh V, Cadranel J., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-38.